Marconi Abreu

Marconi Abreu, M.D. is an Associate Professor in the Department of Internal Medicine at The University of Texas Southwestern Medical Center and serves as Medical Director of the Parkland General Endocrinology Clinic. His clinical expertise centers on advanced diabetes care using technology for Type 1 and Type 2 diabetes management, with secondary focus on adrenal, pituitary, and reproductive endocrine disorders.

Dr. Abreu completed medical training at Universidade Federal Do Bahia (1996-2002), Internal Medicine residency and Chief Residency at University of Connecticut Health Center (2004-2008), and Endocrinology fellowship at UT Southwestern (2012-2015).

• Medical School: Universidade Federal Do Bahia (1996-2002)
• Residency: University of Connecticut Health Center, Internal Medicine (2004-2008)
• Chief Resident: University of Connecticut Health Center (2007-2008)
• Fellowship: UT Southwestern Medical Center, Endocrinology & Metabolism (2012-2015)

His research spans Type 1/2 diabetes pathophysiology, reproductive endocrinology, and adrenal disorders, emphasizing clinical translation through trials like SIMPLE and community initiatives like PRODIBA in Brazil. He investigates diabetes technology integration, pharmaceutical interventions, and medication adherence impacts on metabolic outcomes.

Recent publications (2018-2020) highlight trends in Type 2 diabetes management including SGLT2 inhibitor cardiovascular effects, insulin dosing optimization, digital health applications, and real-world implementation of structured care models across diverse populations.

Dr. Abreu's accolades recognize clinical excellence and community impact:

• Pamela Kisluk Spirit Award (2007) from University of Connecticut
• Exceptional Contributor to Brazilian Community of Taunton, MA (2010)
• Daniel W. Foster, MD Award for Excellence in Clinical Training (2016) from UT Southwestern

His leadership at Parkland Clinic demonstrates commitment to underserved populations, though specific student mentorship details and grant funding mechanisms aren't documented in available materials. Current initiatives focus on expanding diabetes technology access and improving transitional care protocols for high-risk patients.